Trastuzumab deruxtecan for HER2-low metastatic triple‑negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial studies trastuzumab deruxtecan (T‑DXd) as a first treatment for people with HER2‑low, triple‑negative breast cancer that has spread or returned and cannot be fully removed by surgery. It aims to shrink tumors and control the disease while checking safety and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18–70.
- You are well enough to do most normal activities (ECOG score 0–1).
- Your cancer has come back or spread, and it is considered not fully removable with surgery.
- Your tumor tests show triple‑negative breast cancer (HER2 negative, ER negative, and PgR negative) and a specific LAR subtype from the study center’s classification.
- You have at least one measurable tumor spot on scans (RECIST v1.1).
- You have not had radiation (except for comfort pain relief), chemotherapy, immunotherapy, targeted therapy, or endocrine therapy within 3 weeks before starting, and any side effects have recovered (and you do not have significant nerve problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy called trastuzumab deruxtecan for people with advanced breast cancer. It aims to see how well the treatment works and how safe it is.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This study is testing a new drug called trastuzumab deruxtecan (also known as T-DXd) in women with advanced breast cancer that is hormone receptor positive and has a very low level of HER2 (called HER2-ultralow). The trial aims to see if this drug can help shrink or slow the growth of the cancer in this specific group of patients.
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.